Alla Katsnelson | Jun 15, 2009 | 3 min read
In a new initiative that aims to forge broader partnerships between pharma and academia, Eli Lilly has announced that it will conduct free drug development assays in four therapeutic areas on any compounds academic researchers and small biotechs care to send along. In exchange, the company will get first dibs on any licensing deals or collaborations that promising compounds might yield. What differentiates this initiative from the plethora of partnering opportunities out there, Alan Palkowitz,